AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8925352 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose depot haloperidol (25 mg) combined with targeted oral neuroleptics
Number of subjects: 19
Study 8925352 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose depot haloperidol (150 mg) combined with targeted oral neuroleptics
Number of subjects: 19
Study 1562782 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus nutritional oral supplementation (Ensure)
Number of subjects: 23
Study 1562782 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 23
Study 4060730 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 36
Study 4060730 — intervention group
Group type: COMPARATOR
Intervention: Tolazoline (Control)
Number of subjects: 36
Study 3579004 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (enteral formula) in addition to usual diet for 8 weeks
Number of subjects: 21
Study 3579004 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual diet without enteral formula)
Number of subjects: 21
Study 3579004 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of RMF between poorly nourished and well-nourished male patients
Number of subjects: 21
Study 31757519 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nicotine lozenge used 15 minutes before cue exposure
Number of subjects: 58
Study 31757519 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge used 15 minutes before cue exposure
Number of subjects: 58
Study 31757519 — intervention group
Group type: COMPARATOR
Intervention: No treatment until after cue presentation
Number of subjects: 58
Study 29223019 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 221
Study 29223019 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 221
Study 29223019 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of PNI
Number of subjects: 221
Study 29223019 — intervention group
Group type: EXPERIMENTAL
Intervention: Extramural vascular invasion
Number of subjects: 221
Study 29223019 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour budding
Number of subjects: 221
Study 29223019 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥2 adverse biomarkers
Number of subjects: 221
Study 29145890 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg metolazone single dose
Number of subjects: 30
Study 29145890 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg metolazone single dose
Number of subjects: 30
Study 29145890 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg metolazone single dose
Number of subjects: 30
Study 29145890 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg metolazone multiple doses
Number of subjects: 30
Study 29145890 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg metolazone with food effect
Number of subjects: 30
Study 29145890 — intervention group
Group type: EXPERIMENTAL
Intervention: Metolazone (all doses)
Number of subjects: 30
Study 26717214 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait therapy with the Lokomat® system
Number of subjects: 5
Study 24370208 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist medical care plus the Lightning Process (LP)
Number of subjects: 80
Study 24370208 — intervention group
Group type: COMPARATOR
Intervention: Specialist medical care (SMC)
Number of subjects: 80
Study 22333097 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS) inserted immediately after artificial abortion
Number of subjects: 166
Study 22333097 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel-releasing intrauterine system (LNG-IUS) inserted during the period of regular menstruation
Number of subjects: 166
Study 18451188 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefiracetam 900 mg
Number of subjects: 159
Study 18451188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 18451188 — intervention group
Group type: COMPARATOR
Intervention: Nefiracetam 600 mg
Number of subjects: 159
Study 16544963 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 mg bd acetazolamide
Number of subjects: 222
Study 16544963 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg bd acetazolamide
Number of subjects: 222
Study 16544963 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 12816549 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritanserin (10 mg/day) + lithium (1-1.2 mEq/L) + haloperidol (10 mg/day)
Number of subjects: 45
Study 12816549 — intervention group
Group type: COMPARATOR
Intervention: Placebo + lithium (1-1.2 mEq/L) + haloperidol (10 mg/day)
Number of subjects: 45
Study 10750574 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg alendronate daily
Number of subjects: 37
Study 10750574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 9185746 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose MEG-X test (50 mg lidocaine intravenously)
Number of subjects: 70
Study 9185746 — intervention group
Group type: COMPARATOR
Intervention: Standard MEG-X test
Number of subjects: 70
Study 1524688 — intervention group
Group type: EXPERIMENTAL
Intervention: Rembrandt with placebo
Number of subjects: 65
Study 1524688 — intervention group
Group type: COMPARATOR
Intervention: Crest with Peridex
Number of subjects: 65
Study 1524688 — intervention group
Group type: COMPARATOR
Intervention: Crest with placebo
Number of subjects: 65
Study 1524688 — intervention group
Group type: COMPARATOR
Intervention: Peridex groups
Number of subjects: 65
Study 2866788 — intervention group
Group type: EXPERIMENTAL
Intervention: Azepexole 10 mg
Number of subjects: 6
Study 2866788 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 300 micrograms
Number of subjects: 6
Study 2866788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31119206 — intervention group
Group type: EXPERIMENTAL
Intervention: O6-PUFA (soybean oil, 6 g/d)
Number of subjects: 81
Study 31119206 — intervention group
Group type: COMPARATOR
Intervention: O3-PUFA (fish oil, 6 g/d)
Number of subjects: 81
Study 31119206 — intervention group
Group type: EXPERIMENTAL
Intervention: O6-PUFA
Number of subjects: 81
Study 27738125 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including transplant education and engagement activities targeting dialysis facility leadership, staff, and patients conducted from January to December of 2014.
Number of subjects: 9000
Study 27738125 — intervention group
Group type: COMPARATOR
Intervention: Control facilities (no specific intervention mentioned).
Number of subjects: 9000
Study 27738125 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (specifically for black patients).
Number of subjects: 9000
Study 26001894 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous contact lens wear for 12 hours
Number of subjects: 0
Study 26001894 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour contact lens wear stages (C, D, E)
Number of subjects: 0
Study 26001894 — intervention group
Group type: COMPARATOR
Intervention: No contact lenses worn (Stage A)
Number of subjects: 0
Study 26001894 — intervention group
Group type: COMPARATOR
Intervention: Comparison of each 4-hour stage with no-lens response
Number of subjects: 0
Study 24229013 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision after injection of H202 without closure
Number of subjects: 142
Study 24229013 — intervention group
Group type: COMPARATOR
Intervention: Excision and primary closure
Number of subjects: 142
Study 24229013 — intervention group
Group type: COMPARATOR
Intervention: Excision after using hydrogen peroxide (H202) and primary closure
Number of subjects: 142
Study 24229013 — intervention group
Group type: COMPARATOR
Intervention: Excision without closure
Number of subjects: 142
Study 21328327 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib + Pegylated Liposomal Doxorubicin (PLD)
Number of subjects: 0
Study 21328327 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib alone
Number of subjects: 0
Study 19150968 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized test battery for Alzheimer's disease screening
Number of subjects: 174
Study 17225706 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene inhibitors
Number of subjects: 0
Study 15277423 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress testing and 5-year clinical follow-up
Number of subjects: 1123
Study 15277423 — intervention group
Group type: COMPARATOR
Intervention: Follow-up only (Control)
Number of subjects: 1123
Study 11603537 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyapatite (HA) coated femoral stems
Number of subjects: 50
Study 11603537 — intervention group
Group type: COMPARATOR
Intervention: Grit blasted (GB) femoral stems
Number of subjects: 50
Study 11603537 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 9437311 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral carbachol 0.01% (50:50 dilution)
Number of subjects: 41
Study 9437311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 7666122 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg) administered as a single dose for three days
Number of subjects: 142
Study 7666122 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid (amoxicillin 875 mg‐clavulanic acid 125 mg) given b.i.d. for 8 days
Number of subjects: 142
Study 2757896 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline
Number of subjects: 7
Study 2757896 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II with placebo
Number of subjects: 7
Study 2757896 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II with noradrenaline
Number of subjects: 7
Study 2757896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 2757896 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline and Angiotensin II combination
Number of subjects: 7
Study 850321 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol exposure
Number of subjects: 320
Study 850321 — intervention group
Group type: COMPARATOR
Intervention: Control (no diethylstilbestrol exposure)
Number of subjects: 320
Study 30940090 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Simeprevir with ribavirin (n=63) for 12 or 24 weeks
Number of subjects: 599
Study 30940090 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Simeprevir without ribavirin (n=536) for 12 or 24 weeks
Number of subjects: 599
Study 30940090 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of liver disease
Number of subjects: 599
Study 30940090 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 599
Study 28401844 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality foster care
Number of subjects: 111
Study 28401844 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 111
Study 28401844 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (never institutionalized)
Number of subjects: 111
Study 25595665 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy training (1 session per day, 5 days per week, in addition to usual inpatient rehabilitation)
Number of subjects: 30
Study 25595665 — intervention group
Group type: COMPARATOR
Intervention: Reflective listening (same dose as strategy training)
Number of subjects: 30
Study 23973378 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 14
Study 23973378 — intervention group
Group type: COMPARATOR
Intervention: Hydromorphone (HM)
Number of subjects: 14
Study 23973378 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Methadone and Hydromorphone
Number of subjects: 14
Study 21242545 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 131
Study 21242545 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 131
Study 19884223 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-led group treatment
Number of subjects: 259
Study 19884223 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-assisted group treatment
Number of subjects: 259
Study 19884223 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help group treatment
Number of subjects: 259
Study 19884223 — intervention group
Group type: COMPARATOR
Intervention: Waiting list condition
Number of subjects: 259
Study 17239492 — intervention group
Group type: EXPERIMENTAL
Intervention: 0,1,4 month vaccination schedule
Number of subjects: 615
Study 17239492 — intervention group
Group type: COMPARATOR
Intervention: 0,1,6 month vaccination schedule
Number of subjects: 615
Study 17239492 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccination schedules
Number of subjects: 615
Study 14971964 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid carbohydrate (CHO) supplementation
Number of subjects: 9
Study 14971964 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 9
Study 14971964 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid carbohydrate (CHO)
Number of subjects: 9
Study 11346705 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF + EPO
Number of subjects: 40
Study 11346705 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF + EPO
Number of subjects: 40
Study 9040797 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine thrombin (20,000 units)
Number of subjects: 101
Study 9040797 — intervention group
Group type: COMPARATOR
Intervention: No thrombin (control)
Number of subjects: 101
Study 7931444 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 2766 (2 mg/day for 5 consecutive days)
Number of subjects: 42
Study 7931444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 7931444 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Org 2766 vs Placebo
Number of subjects: 42
Study 3060219 — intervention group
Group type: EXPERIMENTAL
Intervention: First screen mammography
Number of subjects: 44718
Study 31954541 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based intervention
Number of subjects: 33
Study 31954541 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-based intervention
Number of subjects: 33
Study 31954541 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 33
Study 29973212 — intervention group
Group type: EXPERIMENTAL
Intervention: AS+SP (artesunate + sulfadoxine-pyrimethamine)
Number of subjects: 248
Study 29973212 — intervention group
Group type: COMPARATOR
Intervention: AS+MQ (artesunate + mefloquine)
Number of subjects: 248
Study 26236767 — intervention group
Group type: EXPERIMENTAL
Intervention: HOPE social media intervention (peer-mentored Facebook groups)
Number of subjects: 556
Study 26236767 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard of care (control group)
Number of subjects: 556
Study 23945719 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to promote prolonged and exclusive breastfeeding
Number of subjects: 11867
Study 23945719 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 11867
Study 21169065 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (cooled to 35°C until trauma assessment completed, then cooled to 33°C for 48 hours)
Number of subjects: 232
Study 21169065 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (treated at normothermia)
Number of subjects: 232
Study 18299490 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional didactic decision aid
Number of subjects: 611
Study 18299490 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic disease trajectory model
Number of subjects: 611
Study 18299490 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both traditional decision aid and chronic disease trajectory model
Number of subjects: 611
Study 18299490 — intervention group
Group type: COMPARATOR
Intervention: Public prostate cancer-specific Web sites (control condition)
Number of subjects: 611
Study 18299490 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 611
Study 17312857 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethoxyethylacrylate-coated circuits + leukocyte filters
Number of subjects: 270
Study 17312857 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypeptide-based heparin-bonded circuits with reduced heparinization
Number of subjects: 270
Study 17312857 — intervention group
Group type: COMPARATOR
Intervention: Control: uncoated circuits
Number of subjects: 270
Study 12869172 — intervention group
Group type: EXPERIMENTAL
Intervention: IABC (Intra-Aortic Balloon Counterpulsation)
Number of subjects: 30
Study 12869172 — intervention group
Group type: EXPERIMENTAL
Intervention: IABC
Number of subjects: 30
Study 11039338 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg gadodiamide
Number of subjects: 83
Study 11039338 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mmol/kg gadodiamide
Number of subjects: 83
Study 11039338 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mmol/kg gadodiamide
Number of subjects: 83
Study 9200320 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol
Number of subjects: 18
Study 9200320 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 18
Study 9200320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8061123 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemosorbtion on Ovosorb, a biospecific antiproteinase haemosorbent containing an immobilized ovomucoid
Number of subjects: 32
Study 2972159 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.030 mg ethinylestradiol + 0.15 mg desogestrel alone (A)
Number of subjects: 19
Study 2972159 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.030 mg ethinylestradiol + 0.15 mg desogestrel + 0.5 mg estriol (B)
Number of subjects: 19
Study 2972159 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.030 mg ethinylestradiol + 0.15 mg desogestrel + 2 mg estriol (C)
Number of subjects: 19
Study 238445 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam hydrochloride
Number of subjects: 0
Study 30950894 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclotorsion compensated SMILE surgery (CC group: 54 eyes)
Number of subjects: 84
Study 30950894 — intervention group
Group type: COMPARATOR
Intervention: Standard SMILE surgery (S group: 30 eyes)
Number of subjects: 84
Study 28385705 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-year specialised treatment (extended early intervention)
Number of subjects: 160
Study 28385705 — intervention group
Group type: COMPARATOR
Intervention: 2-year specialised treatment (step-down care)
Number of subjects: 160
Study 25823909 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml 0.3% silver nitrate
Number of subjects: 60
Study 25823909 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml 0.5% silver nitrate
Number of subjects: 60
Study 25823909 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 ml 0.3% silver nitrate
Number of subjects: 60
Study 23097311 — intervention group
Group type: EXPERIMENTAL
Intervention: SC abatacept (125 mg/week) with methotrexate (combination)
Number of subjects: 100
Study 23097311 — intervention group
Group type: EXPERIMENTAL
Intervention: SC abatacept (125 mg/week) without methotrexate (monotherapy)
Number of subjects: 100
Study 23097311 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term extension (LTE) with SC abatacept and methotrexate (combination)
Number of subjects: 100
Study 23097311 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term extension (LTE) with SC abatacept without methotrexate (monotherapy)
Number of subjects: 100
Study 22046727 — intervention group
Group type: EXPERIMENTAL
Intervention: VR integrated training (VR50)
Number of subjects: 0
Study 22046727 — intervention group
Group type: COMPARATOR
Intervention: Traditional welding training (TW)
Number of subjects: 0
Study 19019556 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mechanical ventilation during the first 72 hours
Number of subjects: 851
Study 19019556 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 851
Study 19019556 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body surface area (BSA) burned
Number of subjects: 851
Study 19019556 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-thickness BSA burned
Number of subjects: 851
Study 19019556 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 851
Study 19019556 — intervention group
Group type: COMPARATOR
Intervention: Mechanism of injury
Number of subjects: 851
Study 19019556 — intervention group
Group type: COMPARATOR
Intervention: Delay to ICBU admission
Number of subjects: 851
Study 16484573 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose AGE (2.4 mL/d)
Number of subjects: 51
Study 16484573 — intervention group
Group type: COMPARATOR
Intervention: Low-dose AGE (0.16 mL/d)
Number of subjects: 51
Study 15333470 — intervention group
Group type: EXPERIMENTAL
Intervention: Red meat intake (highest quintile)
Number of subjects: 37309
Study 15333470 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed meat intake (highest quintile)
Number of subjects: 37309
Study 15333470 — intervention group
Group type: EXPERIMENTAL
Intervention: Total processed meat intake (≥5/week vs. <1/month)
Number of subjects: 37309
Study 15333470 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacon intake (≥2/week vs. <1/week)
Number of subjects: 37309
Study 15333470 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot dogs intake (≥2/week vs. <1/week)
Number of subjects: 37309
Study 10658682 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafts with BCR-ABL/ABL ratio <= 0.01
Number of subjects: 40
Study 10658682 — intervention group
Group type: COMPARATOR
Intervention: Grafts with BCR-ABL/ABL ratio > 0.01
Number of subjects: 40
Study 10658682 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafts with low levels of leukemic cell contamination
Number of subjects: 40
Study 10658682 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest level of contaminated stem cell collections (BCR-ABL/ABL ratio)
Number of subjects: 40
Study 7722710 — intervention group
Group type: EXPERIMENTAL
Intervention: Atole (high-energy, high-protein supplement: 163 kcal/682 kJ and 6.4 g protein per serving)
Number of subjects: 364
Study 7722710 — intervention group
Group type: COMPARATOR
Intervention: Fresco (low-energy, no-protein supplement: 59 kcal/247 kJ per 180 mL)
Number of subjects: 364